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Abstract
Background: Silicone breast implants have long been used for breast augmentation and reconstruction. During this time, these medical devices have
gone through a number of modifications to improve their safety, quality, and clinical outcome performance.
Objectives: The authors conducted a 10-year study to determine the safety and effectiveness of Natrelle 410 silicone breast implants.
Methods: This prospective, multicenter study enrolled 941 subjects who were undergoing either augmentation, augmentation revision, reconstruction,
or reconstruction revision. Data on complications, reoperations, explantations, and subject satisfaction were collected at annual clinic visits, and one-third of
subjects underwent biennial magnetic resonance imaging (MRI) to screen for implant rupture. The authors used the Kaplan-Meier estimator to calculate
risk rates for local complications, reoperations, and explantations.
Results: Capsular contracture rates increased approximately 1% per year from the previously reported 6-year rates. The rates were significantly lower
than those from the Natrelle round gel core study. The overall rate of confirmed ruptured implants in subjects who underwent MRI was 5.7%. Eleven late
seromas were reported. The most common reason for explantation was a subject requesting a size or style change. Satisfaction rates remained high
through 10 years, with most subjects saying they were somewhat or definitely satisfied with their implants.
Conclusions: This 10-year prospective trial demonstrated the long-term safety and effectiveness of Natrelle 410 anatomical form-stable implants. The
complication rates were low and the satisfaction rates were high.
Level of Evidence: 1
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Silicone gel–filled breast implants have been commercially
available for 50 years.1 During this time, these medical
devices have gone through a number of modifications to
improve their safety, quality, and clinical outcome perfor-
mance. The most objective clinical assessment of these
outcome parameters in the United States was obtained
from investigational device exemption studies that were
approved by the US Food and Drug Administration (FDA).
These exemptions allowed use of medical devices in American
women before FDA approval when there was a specific
need. The Natrelle 410 anatomical form-stable silicone-filled
breast implant (Allergan, Inc., Irvine, California), which was
introduced in Europe in 1993 as the Biodimensional Style
410 implant, was the first anatomically shaped silicone
implant to be designed and brought to the market.
The initial 3-year and subsequent 6-year clinical data on
these implants from an investigational device exemption
study initiated in February 2001 have been published previ-
ously.2,3 The Natrelle 410 silicone gel breast implants were
approved by the FDA on February 20, 2013, and the 10-year
study supporting their approval has been completed. The
present report provides updated clinical data through the
completion of the study and represents the first publication
of a completed investigational device exemption study that
provides prospective, long-term data on highly cohesive,
form-stable breast implants.
METHODS
In this 10-year prospective, multicenter study, we examined
the safety and effectiveness of Natrelle 410 breast implants for
augmentation, reconstruction, and revision. Written informed
consent was obtained from all subjects, and multiple institu-
tional review boards provided approval. (the list of the approv-
ing institutional review boards is available online at http://
asj.oxfordjournals.org/supplemental.) The study was regis-
tered at ClinicalTrials.gov (identifier: NCT00690339). Before
the study was initiated, the study sponsor (Allergan, Inc.) con-
ducted a start-up meeting at each investigational site and also
provided written instructions to investigators and study coor-
dinators. In addition, site visits were conducted throughout
the study to ensure adherence to study guidelines.
The study design, inclusion/exclusion criteria, subject
demographics, surgical details, and safety and effectiveness
results through 6 years have been published previously;2–4
thus, the present report will focus on the 10-year results.
Data were captured prospectively at the initial clinic visit
and at visits 4 weeks and 6 months after implantation, as
well as annually thereafter for 10 years. Magnetic reso-
nance imaging (MRI) was conducted 1, 3, 5, 7, and 10
years after implantation in a subset of subjects to assess
silent rupture, with the worst-case rupture assessment by
either the local facility radiologist or central reviewer radiol-
ogist used to calculate rupture rates. Kaplan-Meier risk
rates were calculated for local complications, reoperations,
and implant removal/replacement. These risk rates repre-
sent the cumulative risk of a subject experiencing an
adverse event at any time through 10 years. The primary
measure of effectiveness at 10 years was subject satisfac-
tion. At each study visit, subjects were queried verbally
about satisfaction by the investigator or study coordinator,
and their responses were recorded on a case report form.
Subject satisfaction was evaluated using a nonvalidated
5-point scale ranging from 1 (definitely dissatisfied) to 5
(definitely satisfied).
RESULTS
Subjects
Between February 2001 and February 2002, we enrolled 941
women (492 undergoing primary augmentation, 156 under-
going augmentation revision, 225 undergoing primary
reconstruction, and 68 undergoing reconstruction revision)
at 48 US sites. Of those, 316 subjects were included in the
MRI cohort. More than 90% of subjects were white, and the
median body mass indices (weight in kilograms divided by
height in meters squared) were 20.6, 21.0, 22.6, and 22.4 in
the augmentation, augmentation revision, reconstruction,
and reconstruction revision cohorts, respectively.
For subjects undergoing breast augmentation, the indica-
tion for implant placement was dissatisfaction with breast
size/shape in 79.1%, asymmetry in 10.6%, ptosis in 6.7%,
and aplasia in 3.7%. All of the reconstruction procedures
occurred after mastectomy except for 1 that was performed
after breast trauma. Concurrent procedures were performed
in 7.2% of augmentation, 75.2% of augmentation revision,
53.7% of reconstruction, and 75.2% of reconstruction revi-
sion surgeries, with capsulectomies being the procedure
most often performed. Accompanying mastopexies were
performed in 6.6% of augmentation procedures and 17.7%
of augmentation revision procedures.
The inframammary fold was the most common incision
site for women undergoing augmentation (86.8%) or aug-
mentation revision (75.5%), whereas the mastectomy scar
was the most common incision site for women undergoing
reconstruction (74.9%) or reconstruction revision (54.0%).
Partial submuscular placement was the most frequent loca-
tion in all cohorts (80.5%, 65.8%, 59.9%, and 60.2% for
the augmentation, augmentation revision, reconstruction,
and reconstruction revision cohorts, respectively). In the
augmentation and augmentation revision cohorts, sub-
glandular placement was the second most frequent place-
ment (15.7% and 28.4%, respectively), whereas in the
reconstruction and reconstruction revision cohorts, it was
complete submuscular placement (27.7% and 31.9%,
respectively).
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Pocket irrigation with administration of medications
(most commonly antibiotics) was performed for the majority
of surgeries (61.1%, 66.5%, 79.4%, and 84.1% for the
augmentation, augmentation revision, reconstruction, and
reconstruction revision cohorts, respectively). Most sub-
jects also received parenteral antibiotics (88.6% for women
undergoing augmentation, 93.6% for women undergoing
augmentation revision, 93.3% for women undergoing
reconstruction, and 97.1% for women undergoing recon-
struction revision. Drains were placed in 4.3%, 45.2%,
65.5%, and 61.9% of the augmentation, augmentation re-
vision, reconstruction, and reconstruction revision surger-
ies, respectively.
Follow-up rates at 10 years were 65.8% in the augmenta-
tion cohort, 55.3% in the augmentation revision cohort,
81.1% in the reconstruction cohort, and 78.4% in the
reconstruction revision cohort. The by-implant compliance
rate for the 10-year MRI was 70.1% for augmentation,
64.2% for augmentation revision, 72.3% for reconstruc-
tion, and 80.0% for reconstruction revision subjects.
Safety
Capsular contracture rates (Baker scale grades III and IV)
by subject increased approximately 1% per year from the
previously reported 6-year rates.3 The final 10-year rates
were 9.2% for augmentation, 11.9% for augmentation revi-
sion, 14.5% for reconstruction, and 26.8% for reconstruc-
tion revision (Table 1, Figure 1). The overall rupture rate
(suspected and confirmed) in the MRI cohort was 16.4%
(9.7% of implants). Of the 38 implants included as sus-
pected ruptures, 26 were confirmed to have ruptured at
explantation and 12 remained in vivo, so the rupture was
unconfirmed. Of those, 8 had MRI evidence of a probable
rupture and 4 had indeterminate MRI evidence. In the MRI
cohort across all indications, 9.4% of subjects had ruptures
and 5.7% of implants ruptured (Table 1, Figure 2). All of
the ruptures were intracapsular, with no reports of extrac-
apsular rupture or migrated gel.
The rates of all complications remained low through 10
years, aside from capsular contracture and rupture in <5%
of women undergoing augmentation. For women who
underwent augmentation revision, the only other major
complications (>5%) were implant malposition (9.1%) and
asymmetry (6.9%). The seroma rate ranged from 1.6% in
augmentation subjects to 6.2% in reconstruction revision
subjects. Eleven seromas occurred >1 year after implanta-
tion, which means that 0.6% of the 1760 devices implanted
developed a late seroma (ranging from 0.4% in augmenta-
tion subjects to 0.9% in reconstruction revision subjects).
Onset dates for these seromas ranged from 1.4 to 7.6 years
after implantation, with most occurring at approximately
6 years.
A single case of breast implant–associated anaplastic
large cell lymphoma (BIA-ALCL) was reported. The subject
had a strong family history of breast cancer and fibrocystic
disease and had been diagnosed with intraductal hyperpla-
sia before a simple mastectomy. She had undergone breast
reconstruction and was in the 10th year of her follow-up
when treatment of a late seroma led to the discovery of
ALCL. The cells were detected in the seroma fluid and the
subject underwent bilateral implant removal and complete
capsulectomies. No tumor cells were detected in the cap-
sules, the subsequent positron emission tomography scan
was normal, and no adjuvant treatment was given. The
subject has shown no evidence of recurrence in 3 years of
follow-up.
Reoperation rates increased approximately 3% per year
from the 6-year rates, and the most common reasons for
reoperation were subjects requesting a style or size change
(augmentation), capsular contracture and implant malposi-
tion (augmentation revision), scarring (reconstruction), and
capsular contracture (reconstruction revision). Explantations
were most often performed in response to subjects request-
ing a style or size change in all cohorts except the reconstruc-
tion revision cohort, in which capsular contracture resulted
in more explantations (Table 2). No gel fractures were
reported at explantation. Eighty-seven percent of subjects
had their implants replaced after removal, and of those who
had another 410 implant as the replacement, 60% went to a
larger implant, whereas 15%went to a smaller implant.
Investigators performed device assessments and reported
that at 10 years, the shape of the breast reflected the shape
of the implant for 97.3%, 95.8%, 91.8%, and 100% of the
augmentation, augmentation revision, reconstruction, and
reconstruction revision cohorts, respectively. Similarly,
they reported that the implants had maintained their origi-
nal position for 96.9%, 93.0%, 94.8%, and 94.9% of
subjects, respectively. This was visually demonstrated with
photographic examples of subjects at baseline and at
10 years, along with an accompanying MRI image from the
10-year visit (Figures 3–6).
Satisfaction
Satisfaction rates remained high through 10 years, with
96.2%, 87.5%, 93.3%, and 90.0% of subjects saying they
were somewhat or definitely satisfied with their implants
for the augmentation, augmentation revision, reconstruc-
tion, and reconstruction revision cohorts, respectively
(Table 3). Investigators provided similarly high satisfaction
scores.
DISCUSSION
The Natrelle 410 implant was the first fifth-generation
breast implant developed,2 and it differs from prior
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implants in a number of ways. Rather than a single-shaped,
mandrel-designed implant differentiated only by the size
(volume) of the round mandrel, the Natrelle 410 is anatomi-
cally shaped, with 12 dimensional options that allow for a
combination of 3 different heights and 4 different projec-
tions. This diversity of implant types (termed “cells”)
allows for an individualized approach to suit patient needs.
Four of the 12 cells were available and used for the current
investigational device exemption study: moderate height
and projection, full height and projection, moderate height
and full projection, and full height and moderate projec-
tion. The 410 implant is differentiated from the fourth-
generation implants by its highly cohesive, form-stable sili-
cone gel filler (TruForm 3 gel; Allergan, Inc.).5,6 A greater
degree of crosslinking of the silicone polymers during the
manufacturing process determines the firmness, or cohesiv-
ity, of the silicone gel. When oriented in a vertical position,
the 410 implants are said to be form-stable, maintaining
their dimensions and form (ie, gel distribution within the
shell), and are characterized by the lack of collapse of the
upper pole of the breast implant.5,6 The textured surface of
the 410 implant, termed Biocell (Allergan, Inc.), was specifi-
cally created to help maintain implant stability and position
within the body. Biocell is a macrotexture surface with irreg-
ular depressions that have an average diameter of 300 μm,7
and it demonstrates an adhesive effect with surrounding
native tissue after surgical implantation.8 Together, these
properties mark a distinct departure from previous genera-
tions of breast implants by providing adequate shape stabil-
ity to prevent significant implant collapse and a sufficiently
textured surface to help hold implant position.
One of the most commonly reported complications in
breast surgery is capsular contracture. The risk of this
complication increases over time9–11 and is reflected in the
Table 1. Kaplan-Meier Key Risk Rates by Subject Group Through 10 Yearsa
Complication Augmentation Cohort,
% (95% CI) (n = 492)
Augmentation Revision Cohort,
% (95% CI) (n = 156)
Reconstruction Cohort,
% (95% CI) (n = 225)
Reconstruction Revision Cohort,
% (95% CI) (n = 68)
Key risk rates
Reoperation 29.7 (25.6-34.3) 47.3 (39.2-56.0) 54.6 (47.9-61.6) 48.5 (37.0-61.5)
Implant removal with replacement 16.8 (13.6-20.8) 27.8 (21.0-36.2) 34.3 (28.0-41.6) 39.3 (28.2-52.9)
Implant removal without replacement 3.3 (1.9-5.7) 5.9 (2.8-12.2) 6.7 (3.8-11.7) 4.9 (1.2-18.7)
Implant rupture (MRI cohort) 17.7 (11.7-26.4) 14.7 (5.4-36.4) 12.4 (6.0-24.4) 19.6 (7.8-44.4)
Confirmed implant rupture (MRI cohort) 10.2 (6.0-17.0) 5.2 (1.3-19.4) 9.5 (4.4-19.9) 10.1 (2.6-34.7)
Capsular contracture (Baker grade III/IV) 9.2 (6.7-12.6) 11.9 (7.2-19.3) 14.5 (10.1-20.6) 26.8 (16.8-41.1)
Additional risk rates occurring in ≥2.0% of subjects
Implant malposition 4.7 (3.1-7.3) 9.1 (5.2-15.6) 5.7 (3.1-10.5) 8.0 (3.0-20.5)
Breast pain 4.5 (2.8-7.1) 5.2 (2.3-11.5) 8.2 (4.9-13.7) 7.8 (2.9-20.4)
Swelling 4.0 (2.5-6.3) 2.7 (1.0-7.1) 5.3 (2.8-9.7) 3.2 (0.8-12.4)
Infection 1.7 (0.8-3.3) 2.1 (0.7-6.3) 6.1 (3.5-10.7) 8.5 (3.6-19.5)
Seroma/fluid accumulation 1.6 (0.8-3.3) 3.2 (1.2-8.4) 2.8 (1.1-6.6) 6.2 (2.4-15.8)
Hypertrophic/abnormal scarring 1.4 (0.6-3.0) 3.7 (1.5-8.8) 4.8 (2.6-8.7) 3.2 (0.8-12.3)
Hematoma 1.3 (0.6-2.9) 2.0 (0.6-6.0) 1.0 (0.3-4.0) 0
Delayed wound healing 1.1 (0.4-2.5) 1.3 (0.3-5.1) 0.5 (0.1-3.3) 2.9 (0.7-11.3)
Asymmetry 1.2 (0.5-2.9) 6.9 (3.6-13.1) 12.4 (8.4-18.1) 17.4 (9.6-30.5)
Wrinkling/rippling 0.9 (0.3-2.4) 3.7 (1.5-8.6) 6.2 (3.3-11.4) 12.8 (6.1-25.6)
Redness 0.6 (0.2-2.0) 0 0.9 (0.2-3.7) 4.9 (1.6-14.7)
Implant palpability/visibility 0.3 (0.0-1.8) 1.4 (0.3-5.4) 1.2 (0.3-4.7) 4.2 (1.0-16.5)
Upper pole fullness 0 0.7 (0.1-4.5) 4.2 (2.2-7.8) 1.5 (0.2-10.1)
CI, confidence interval; MRI, magnetic resonance imaging.aData are presented as rate (95% CI).
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slightly increased capsular contracture rates reported herein
from 6 years to 10 years.3 However, the 10-year rates (9.2%,
11.9%, 14.5%, and 26.8% for the augmentation, augmenta-
tion revision, reconstruction, and reconstruction revision
cohorts, respectively) are lower than those observed in the
Natrelle round gel (fourth generation) core study, which in-
cluded predominately smooth implants (56.2%).12 The cap-
sular contracture rate for the 410 implant at 10 years was
51% lower (9.2% vs 18.9%) than that reported at 10 years
in the Natrelle round gel core study for primary breast aug-
mentation.12 Further, a 59% lower incidence of capsular
contracture was noted for breast augmentation revision
with the 410 implant compared with the Natrelle round
gel implant (11.9% vs 28.7%, respectively) at 10 years.12
Similarly, in 6-year clinical trial data of the form-stable
Contour Profile Gel (CPG) implant (Mentor Worldwide LLC,
Santa Barbara, California), lower contracture rates were re-
ported for the CPG implant than for Mentor’s predominately
smooth-surface round gel breast implants.13 Although
these studies were not direct comparisons between form-
stable and non–form-stable implants and no causation can
be assigned, it is of interest that form-stable implants ap-
peared to have lower rates of capsular contracture.
Careful preoperative planning and improvements in sur-
gical technique also have been reported to decrease rates of
capsular contracture. Most 410 implants used for augmen-
tation and augmentation revision in this study were placed
via an incision in the inframammary fold, which has been
independently shown to have lower capsular contracture rates
than other incision placement locations.14–16 Submuscular
placement and antibiotic pocket irrigation is advocated, as
well as the “no-touch” technique of implantation. Although it
cannot be documented that this process was utilized in every
subject in this study, these principles and techniques were
taught for the use of this implant and were conveyed to the
independent investigators. These factors have also been inde-
pendently documented to reduce capsular contracture with
all implants.17,18
Figure 1. These Kaplan-Meier curves show the risk of capsular contracture through 10 years.
Figure 2. These Kaplan-Meier curves show the risk of implant rupture through 10 years. MRI, magnetic resonance imaging.
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Incorporation of these techniques facilitates the charac-
teristics of the implant, which reduces capsular contrac-
ture. The direct contact with the Biocell textured surface,
supported by the firmness of the highly cohesive gel, and
its engagement with a surgically created vascular host
pocket frequently allows for tissue adherence and immobil-
ity with softness.8,19 These findings, first established with
Biocell tissue expanders, are more likely to occur with the
410 implant than with less cohesive, round, textured
implants in a less precise surgical pocket. Furthermore, the
reduced rate of capsular contracture with the Natrelle 410
implant and the clinically appreciated softness has been
described as providing a one breast feel as compared with
a round implant moving in its larger pocket separate from
the movement of the overlying breast and soft tissue.20
Although the firmer gel of the 410 implant could mask the
feel of some mild capsular contracture formation, it is clear
that when the 410 implant was used properly, it had the
lowest 10-year rate of capsular contracture of any implant
studied thus far in an FDA-approved registration trial. These
data also further supported the recent finding that Biocell-
covered 410 implants have a statistically lower rate of
capsular contracture than do smooth fourth-generation
round gel implants used for primary augmentation.21 These
results are in agreement with those from previous publica-
tions, which showed improved rates of capsular contracture
in textured implants compared with smooth implants.22–28
Although these implants feel soft in the body, the
10-year data show a very low rate of implant rippling or
wrinkling (0.9% for augmentation, 3.7% for augmentation
revision, 6.2% for reconstruction, and 12.8% for recon-
struction revision). These data corroborated previously
published data, which demonstrated that the Natrelle 410
implants have low rates of wrinkling compared with other-
shaped implants. Indeed, in a comparative study, Jewell
and Jewell29 reported a 5-fold higher rate of rippling in the
CPG implant group compared with the 410 implant group.
In a separate study of the 410 implant, wrinkling was
reported in 5% of subjects after a mean of 8 years.30
Another important finding in this 10-year study is the
low malposition rate of the shaped 410 implant, reported
herein at 4.7% for augmentation, 9.1% for augmentation
revision, 5.7% for reconstruction, and 8.0% for reconstruc-
tion revision. It should be noted that rotation is a subset of
Table 2. Primary Reasons for Reoperation and Explantation
Reason % of Augmentation
Cohort
% of Augmentation
Revision Cohort
% of Reconstruction
Cohort
% of Reconstruction
Revision Cohort
Reasons for reoperation occurring in >8% of reoperations
No. of reoperations 167 83 163 40
Subject request for style/size change 13.2 8.4 7.4 10.0
Capsular contracture 11.4 14.5 12.3 22.5
Suspected rupture 11.4 12.0 9.8 7.5
Implant malposition 10.2 14.5 12.3 10.0
Scarring 9.0 8.4 19.0 2.5
Need for biopsy 8.4 13.3 7.4 5.0
Ptosis 7.8 8.4 3.7 0
Reasons for implant removal (with or without replacement) occurring in >8% of explantations
No. of explantations 153 78 115 40
Subject request for style/size change 34.0 24.4 20.9 20.0
Suspected rupture 13.7 16.7 14.8 7.5
Ptosis 11.1 5.1 1.7 0
Capsular contracture 9.8 23.1 15.7 25.0
Asymmetry 4.6 6.4 11.3 2.5
Implant malposition 4.6 9.0 11.3 7.5
Wrinkling/rippling 0.7 0 5.2 15.0
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malposition, and thus the rate of postoperative rotation is
even lower. This low malposition rate likely reflects the
utility of Biocell in maintaining the correct anatomical
alignment within the recipient and minimizing postopera-
tive implant rotation.8,31 However, this tissue adherence to
the Biocell surface does not always occur, and therefore
rotation of the shaped device is possible. To this point, in a
recent study using high-resolution ultrasound rather than
MRI, Schafer et al32 reported higher-than-expected rotation
rates for shaped breast implants (21% and 25% for the 410
and CPG implants, respectively). The study authors noted
this was a dynamic process, with the majority of rotations
expected to self-reverse.33
The 10-year seroma rate was also quite low in our study
(1.6% for augmentation, 3.2% for augmentation revision,
2.8% for reconstruction, and 6.2% for reconstruction revi-
sion), with 11 seromas occurring >1 year after surgery
(0.6%). The confirmed rupture rate in the MRI cohort for
all indications was 9.4% for subjects and 5.7% for implants
at 10 years, and there was no report of extracapsular sili-
cone gel through the 10 years of the study.
Figure 3. This 33-year-old woman is shown before (A, C) and 10 years (B, D) after breast augmentation with 255-cc Natrelle 410
moderate height, full projection implants.
Figure 4. Magnetic resonance imaging scan taken 10 years
after breast augmentation with 255-cc Natrelle 410 moderate
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In recent years, increased awareness of BIA-ALCL, a rare
ALCL subset, has been noted. In 1 study, the incidence of
BIA-ALCL was estimated to be 0.1-0.3 per 100,000 women
with implants per year.34 Although the etiology of this
condition is not yet known, it is distinct from systemic
ALCL and typically characterized by early detection, an
indolent course, and high rates of complete remission after
treatment via implant removal and capsulectomy.35 Cases
of BIA-ALCL have been reported across implant types
(smooth, textured, saline, silicone), across manufacturers,
and in subjects with and without prior implant history;
however, more cases have been reported with textured-
surface devices. In the present study, 1 subject in her 10th
year of follow-up presented with BIA-ALCL that was
detected in seroma fluid. She was conservatively treated
with bilateral capsulectomies and implant removal. She
remains disease-free without any evidence of recurrence.
Despite the many advantages reported herein of the
firmer, greater crosslinked silicone gel implant compared
with fourth-generation round implants, it has been ques-
tioned whether these implants impart a firmer feel within
the body. Perhaps one can accept this tradeoff for a lower
capsular contracture rate, with a documented safe implant,
and a better shape to the breast, particularly in subjects
Figure 5. This 36-year-old woman is shown before (A, C) and 10 years after (B, D) breast reconstruction with a bilateral neopec-
toral pocket conversion and placement of 255-cc Natrelle 410 full height, full projection implants.
Figure 6. Magnetic resonance imaging scan taken 10 years after
breast reconstruction with a bilateral neopectoral pocket conver-
sion and placement of 255-cc Natrelle 410 full height, full projec-
tion implants in the 36-year-old woman shown in Figure 5.
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who have minimal breast tissue and a tighter tissue enve-
lope or in reconstruction subjects in whom the entire breast
is essentially an implant. Although our clinical data did not
directly capture subject-perceived firmness, 96.2% of aug-
mentation subjects reported they were somewhat or defi-
nitely satisfied with their implants at 10 years. These
percentages were 87.5% for women who underwent aug-
mentation revision, 93.3% for women who underwent
reconstruction, and 90.0% for women who underwent re-
construction revision. In addition, in an earlier publication
that focused on augmentation, Gladfelter and Murphy4
showed that women who had undergone augmentation
reported improved satisfaction with the feel of their breasts
after implantation. There were similar levels of improve-
ment in subject satisfaction with regard to breast feel
among subjects who underwent reconstruction.
It is important to note that there is a potential for bias in
studies that rely on self-reported data. The investigators in
the present study were experienced surgeons who had spe-
cific experience with shaped breast implants. Although
there may be inconsistency in reporting among investiga-
tors within the study, individual investigators are likely to
be fairly consistent in their reporting. Despite the limita-
tions inherent to studies such as this, the results of con-
trolled, monitored studies are likely less biased than are
results obtained from retrospective reviews. It is also worth
noting that the present study was source data monitored
and conducted under the purview of the FDA.
CONCLUSION
In the present 10-year prospective trial, Natrelle 410 ana-
tomical form-stable implants demonstrated long-term
safety and effectiveness, with low complication rates and
high satisfaction rates. These implants provide further
options to match physician and patient needs.
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Table 3. Subject Satisfaction at 10 Years
Satisfaction Level % of Augmentation Cohort % of Augmentation Revision
Cohort
% of Reconstruction Cohort % of Reconstruction Revision
Cohort
Definitely dissatisfied (1) 1.4 2.8 1.5 0
Somewhat dissatisfied (2) 2.1 8.3 2.2 7.5
Neither satisfied nor dissatisfied (3) 0.3 1.4 3.0 2.5
Somewhat satisfied (4) 7.2 16.7 17.9 22.5
Definitely satisfied (5) 89.0 70.8 75.4 67.5
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